Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.60 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538032 | 0.99 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL6440668 | 0.99 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL3048640 | 0.98 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL7595258 | 0.98 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL7597409 | 0.94 | CYSLTR1 (0.70) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL8451432 | 0.93 | FFAR1 (0.62) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL7594231 | 0.92 | CYSLTR1 (0.71) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL8311452 | 0.92 | FFAR1 (0.64) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL7597420 | 0.91 | CYSLTR1 (0.70) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 | |
| SCHEMBL8451447 | 0.91 | FFAR1 (0.62) | CYSLTR1CYSLTR2FFAR1AKR1B1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0862557-B1 | SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 2002-11-27 | — | — | EP | claimed |
| US-5795900-A | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1998-08-18 | — | — | US | claimed |
| EP-1892239-B1 | Inhibitors of cytosolic phospholipase A2 | WYETH LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-1891006-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2248801-A1 | Inhibitors of cytosolic phospholipase a2 | Wyeth LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7713964-B2 | Methods for treating asthmatic conditions | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7557135-B2 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1892239-A1 | Inhibitors of cytosolic phospholipase A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1451154-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0862557-B1 | SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 2002-11-27 | — | — | EP | disclosed |
| US-5843968-A | Symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1998-12-01 | — | — | US | disclosed |
| US-5795900-A | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | CYSLTR1 31/4885CYSLTR2 25/4885FFAR1 541/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | CYSLTR1 252/4885CYSLTR2 120/4885FFAR1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.